{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tiotropium+Bromide+Inhalation+Powder",
    "query": {
      "intervention": "Tiotropium Bromide Inhalation Powder"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 35,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tiotropium+Bromide+Inhalation+Powder&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T02:53:52.092Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01124422",
      "title": "Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "fluticasone propionate/salmeterol inhalation powder DISKUS 250/50",
          "type": "DRUG"
        },
        {
          "name": "tiotropium bromide inhalation powder HandiHaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 255,
      "start_date": "2010-07-19",
      "completion_date": "2011-05-02",
      "has_results": true,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01124422"
    },
    {
      "nct_id": "NCT02796677",
      "title": "AMPLIFY - D6571C00001 Duaklir USA Phase III Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)",
          "type": "DRUG"
        },
        {
          "name": "Aclidinium bromide 400 μg (AB 400 μg)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol fumarate 12 μg (FF 12 μg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg",
          "type": "OTHER"
        },
        {
          "name": "Tiotropium 18 μg (TIO 18 μg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to TIO 18 μg",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "40 Years to 130 Years"
      },
      "enrollment_count": 1595,
      "start_date": "2016-07-05",
      "completion_date": "2017-06-08",
      "has_results": true,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 85,
      "location_summary": "Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more",
      "locations": [
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796677"
    },
    {
      "nct_id": "NCT01587079",
      "title": "Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT003",
          "type": "DRUG"
        },
        {
          "name": "PT001",
          "type": "DRUG"
        },
        {
          "name": "PT005",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium inhalation powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 159,
      "start_date": "2012-04",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2016-06-30",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 19,
      "location_summary": "Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01587079"
    },
    {
      "nct_id": "NCT01202188",
      "title": "A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "indacaterol and glycopyrronium (QVA149)",
          "type": "DRUG"
        },
        {
          "name": "glycopyrronium (NVA237)",
          "type": "DRUG"
        },
        {
          "name": "indacaterol (QAB149)",
          "type": "DRUG"
        },
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 2144,
      "start_date": "2010-09",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-09-09",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 14,
      "location_summary": "Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Troy",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01202188"
    },
    {
      "nct_id": "NCT02799784",
      "title": "An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "TIO/OLO",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 236,
      "start_date": "2016-07-14",
      "completion_date": "2017-04-27",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 9,
      "location_summary": "Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02799784"
    },
    {
      "nct_id": "NCT00424528",
      "title": "Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Bronchitis",
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "Arformoterol Tartrate Inhalation Solution",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Arformoterol and Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 235,
      "start_date": "2006-12",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2012-06-04",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 28,
      "location_summary": "Jasper, Alabama • Tucson, Arizona • San Diego, California + 25 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "DeFuniak Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00424528"
    },
    {
      "nct_id": "NCT00668772",
      "title": "Tiotropium/Salmeterol Inhalation Powder in COPD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tiotropium/Salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 207,
      "start_date": "2008-04-15",
      "completion_date": "2008-11-21",
      "has_results": true,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 16,
      "location_summary": "Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00668772"
    },
    {
      "nct_id": "NCT05165485",
      "title": "Phase 4 COPD and Suboptimal Inspiratory Flow Rate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Revefenacin",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Revefenacin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theravance Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 404,
      "start_date": "2022-01-07",
      "completion_date": "2023-11-20",
      "has_results": true,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 76,
      "location_summary": "Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05165485"
    },
    {
      "nct_id": "NCT06254664",
      "title": "Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Tiotropium 18 µg inhalation powder, hard capsule",
          "type": "DRUG"
        },
        {
          "name": "Zephir inhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Xiromed LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 116,
      "start_date": "2022-10-03",
      "completion_date": "2023-10-27",
      "has_results": false,
      "last_update_posted_date": "2024-02-12",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 8,
      "location_summary": "Fort Myers, Florida • Kissimmee, Florida • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06254664"
    },
    {
      "nct_id": "NCT05161156",
      "title": "Bioequivalence Study of Tiotropium Bromide Inhalation Powder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Test Product (tiotropium bromide inhalation powder)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "18 mcg of Spiriva (Reference Product)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Phargentis SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2022-03-24",
      "completion_date": "2022-11-29",
      "has_results": false,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-09-15T02:53:52.092Z",
      "location_count": 3,
      "location_summary": "Anderson, South Carolina • Gaffney, South Carolina • Union, South Carolina",
      "locations": [
        {
          "city": "Anderson",
          "state": "South Carolina"
        },
        {
          "city": "Gaffney",
          "state": "South Carolina"
        },
        {
          "city": "Union",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05161156"
    }
  ]
}